S. Gail Eckhardt

2.4k total citations
46 papers, 1.3k citations indexed

About

S. Gail Eckhardt is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Gail Eckhardt has authored 46 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 19 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Gail Eckhardt's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (5 papers). S. Gail Eckhardt is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (5 papers). S. Gail Eckhardt collaborates with scholars based in United States, Hungary and Canada. S. Gail Eckhardt's co-authors include D. Ross Camidge, Lia Gore, Cindy L. O’Bryant, Eric K. Rowinsky, Sami Diab, E. Gabriela Chiorean, Nancy Lewis, Laura Q.M. Chow, Natalie J. Serkova and Floyd E. Fox and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

S. Gail Eckhardt

42 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Gail Eckhardt United States 14 779 686 470 302 179 46 1.3k
Marlies H.G. Langenberg Netherlands 15 749 1.0× 604 0.9× 417 0.9× 367 1.2× 128 0.7× 34 1.3k
Giorgia Migliardi Italy 18 719 0.9× 515 0.8× 352 0.7× 277 0.9× 180 1.0× 28 1.3k
Gregory Friberg United States 18 722 0.9× 504 0.7× 318 0.7× 269 0.9× 156 0.9× 35 1.2k
S. Vignati Italy 15 793 1.0× 879 1.3× 569 1.2× 388 1.3× 91 0.5× 22 1.6k
Tae-You Kim South Korea 24 689 0.9× 678 1.0× 420 0.9× 277 0.9× 299 1.7× 48 1.5k
J.L. Breau France 9 778 1.0× 385 0.6× 468 1.0× 207 0.7× 170 0.9× 21 1.2k
E.L. Kwak United States 12 631 0.8× 414 0.6× 501 1.1× 212 0.7× 212 1.2× 31 1.2k
Ruth Riisnaes United Kingdom 15 497 0.6× 786 1.1× 667 1.4× 479 1.6× 198 1.1× 42 1.5k
Ernesto Wasserman United States 17 812 1.0× 418 0.6× 358 0.8× 377 1.2× 114 0.6× 35 1.2k
Haitian Quan China 17 662 0.8× 492 0.7× 383 0.8× 137 0.5× 136 0.8× 30 1.3k

Countries citing papers authored by S. Gail Eckhardt

Since Specialization
Citations

This map shows the geographic impact of S. Gail Eckhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Gail Eckhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Gail Eckhardt more than expected).

Fields of papers citing papers by S. Gail Eckhardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Gail Eckhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Gail Eckhardt. The network helps show where S. Gail Eckhardt may publish in the future.

Co-authorship network of co-authors of S. Gail Eckhardt

This figure shows the co-authorship network connecting the top 25 collaborators of S. Gail Eckhardt. A scholar is included among the top collaborators of S. Gail Eckhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Gail Eckhardt. S. Gail Eckhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Diamond, Jennifer R., Todd M. Pitts, Dana Ungermannova, et al.. (2021). Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Molecular Cancer Therapeutics. 21(3). 397–406. 10 indexed citations
2.
Corr, Bradley R., Jose M. Pacheco, S. Lindsey Davis, et al.. (2021). Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.. Journal of Clinical Oncology. 39(15_suppl). 3075–3075. 4 indexed citations
3.
Gera, Lajos, John J. Tentler, S. Gail Eckhardt, et al.. (2015). Development of Novel Broad Spectrum Anticancer Small Molecule Peptidomimetics with Nanomolar Activity. 241–244. 1 indexed citations
4.
Lieu, Christopher H., Lindsay A. Renfro, Aimery de Gramont, et al.. (2013). The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program. European Journal of Cancer. 49. 3 indexed citations
5.
Pitts, Todd M., S. Lindsey Davis, S. Gail Eckhardt, & Erica L. Bradshaw‐Pierce. (2013). Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. Pharmacology & Therapeutics. 142(2). 258–269. 75 indexed citations
6.
Sullivan, Kelly D., Ryan E. Henry, Christopher C. Porter, et al.. (2012). ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature Chemical Biology. 8(7). 646–654. 56 indexed citations
7.
Jänne, Pasi A., David S. Boss, D. Ross Camidge, et al.. (2011). Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research. 17(5). 1131–1139. 149 indexed citations
8.
Lam, Elaine T., S. Gail Eckhardt, Wells A. Messersmith, et al.. (2011). Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). C18–C18. 2 indexed citations
9.
Láng, István, Zsuzsanna Kahán, Tamás Pintér, et al.. (2010). Az emlőrák belgyógyászati onkológiai (gyógyszeres) kezelése. PubMed. 54(3). 237–254. 4 indexed citations
10.
Kobayashi, Hiroyuki, S. Gail Eckhardt, Jennifer A. Lockridge, et al.. (2005). Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 56(4). 329–336. 28 indexed citations
11.
Eckhardt, S. Gail. (2005). [Clinical studies with imatinib in 2004].. PubMed. 146(18 Suppl 1). 941–4. 1 indexed citations
12.
Eckhardt, S. Gail. (2003). [Perspectives for the hormonal therapy of breast cancer].. PubMed. 47(2). 133–40.
13.
Hidalgo, Manuel, Elżbieta Izbicka, S. Gail Eckhardt, et al.. (1999). Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anti-Cancer Drugs. 10(9). 837–844. 20 indexed citations
14.
Eckardt, John R., S. Gail Eckhardt, Miguel A. Villalona‐Calero, Ronald Drengler, & D. Von Hoff. (1995). New anticancer agents in clinical development.. PubMed. 9(11). 1191–8; 1331; discussion 1332. 9 indexed citations
15.
Scheithauer, Werner, D. Depisch, Gabriela Kornek, et al.. (1994). Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer. 73(6). 1562–1568. 23 indexed citations
16.
17.
Look, Katherine Y., Gregory P. Sutton, Yutaka Natsumeda, et al.. (1992). Inhibition by tiazofurin of inosine 5′-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas. Gynecologic Oncology. 47(1). 66–70. 10 indexed citations
18.
Ottó, Szabolcs, et al.. (1990). Early Detection of Colorectal Cancer. Oncology. 47(3). 209–214. 11 indexed citations
19.
Eckhardt, S. Gail. (1968). [Chemotherapy of tumorous diseases].. PubMed. 109(19). 1009–19. 1 indexed citations
20.
Eckhardt, S. Gail, et al.. (1963). EFFECT OF 1,6-DIBROMO-1,6-DIDEOXY-D-MANNITOL ON CHRONIC GRANULOCYTIC LEUKEMIA.. PubMed. 33. 57–61. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marlies H.G. Langenberg Breakdown of academic impact, for papers by Giorgia Migliardi Breakdown of academic impact, for papers by Gregory Friberg Breakdown of academic impact, for papers by S. Vignati Breakdown of academic impact, for papers by Tae-You Kim Breakdown of academic impact, for papers by J.L. Breau Breakdown of academic impact, for papers by E.L. Kwak Breakdown of academic impact, for papers by Ruth Riisnaes Breakdown of academic impact, for papers by Ernesto Wasserman Breakdown of academic impact, for papers by Haitian Quan
Rankless by CCL
2026